ATV/r+RAL (DT) after failure with NNRTI
Abstract
Background: Dual therapy has emerged as a novel concept for HIV treatment. Thisstudy was aimed at comparing a nucleoside-sparing dual regimen consisting of ATV/r + RAL (DT) vs standard therapy of ATV/r + TDF/FTC (TT) among individuals failing first NNRTI-containing treatment.
Methods: Randomized multicenter open-label pilot study. Primary outcome: proportion of subjects with plasma HIV-1 RNA below the limit of detection (<50 copies/mL) at 48 weeks (W48). Secondary outcomes: proportion of discontinuation due to adverse events (AEs), time until viral suppression, time until loss of virological response, development of integrase resistance mutations, and absolute change in CD4 counts. The primary outcome was analyzed using the FDA snapshot analysis.
Results: Out of 57 participants screened, 34 were randomized to receive: DT (n: 18) or TT (n: 16). At W48, virological response was achieved in 67% (n: 12/18) of participants receiving DT and 88% (n: 14/16) receiving TT by FDA snapshot analysis (p = NS) and 73% and 93% by per-protocol analysis (p = NS). CD4 cell count median change from baseline to W48 was +119 and + 52 cell/μL in DT and TT, respectively. Four participants receiving DT and one TT presented virological failure at W48, with low pVL. One participant developed an integrase resistance mutation (155H) and suppressed later on TT.
Conclusion: ATV/r+RAL as second-line therapy showed a trend to more frequent virological failure, compared to TT, although the study was unpowered to prove this difference. No major differences were seen in tolerance or toxicity.
This study is registered with ClinicalTrials.gov, Number: NCT01829802
Downloads
References
2. van Welzen BJ, Oomen PGA, Hoepelman AIM. Dual Antiretroviral Therapy—All Quiet Beneath the Surface? Front Immunol [Internet]. 2021 [citado 17 de marzo de 2023];12. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2021.637910
3. Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 3 de mayo de 2018;19(7):713-38. https://pubmed.ncbi.nlm.nih.gov/29676935/
4. de Miguel Buckley R, Montejano R, Stella-Ascariz N, Arribas JR. New Strategies of ARV: the Road to Simplification. Curr HIV/AIDS Rep. febrero de 2018;15(1):11-9. https://pubmed.ncbi.nlm.nih.gov/29353398/
5. Badowski M, Pérez SE, Silva D, Lee A. Two’s a Company, Three’s a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Naïve and Treatment-Experienced Patients Living with HIV-1. Infect Dis Ther. June 2020;9(2):185-208.6.FDA(US). Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment [Internet]. FDA; 2017 jul. https://www.fda.gov/media/93373/download
7. World Health Organization UUNCsFU. Scaling up priority HIV/AIDS interventions in the health sector - Progress Report. 2011. https://apps.who.int/iris/handle/10665/43654
8. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS Lond Engl. 13 de noviembre de 2011;25(17):2113-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515052/
9. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. febrero de 2013;29(2):256-65. https://pubmed.ncbi.nlm.nih.gov/22730929/
10. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13(3):119-30. https://pubmed.ncbi.nlm.nih.gov/22592092/
11. Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. J Int Assoc Physicians AIDS Care Chic Ill 2002. 2009;8(2):87-92. https://pubmed.ncbi.nlm.nih.gov/19270153/
12. Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther. 1 de octubre de 2010;15(7):1035-8. https://pubmed.ncbi.nlm.nih.gov/21041919/
13. van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, et al. Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr 1999. 15 de abril de 2016;71(5):538-43. https://pubmed.ncbi.nlm.nih.gov/26605505/
14. Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, et al. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. J Clin Virol Off Publ Pan Am Soc Clin Virol. Feb 2017;87:30-6. https://pubmed.ncbi.nlm.nih.gov/27992788/
